Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Puntos clave

• MAIN FINDING: The study evaluates the effectiveness of CDK2/4/6 inhibitor PF-06873600 in breast cancer patients.
• KEY EVIDENCE: Best overall and confirmed objective responses were assessed using RECIST criteria by investigators.
• APPROACH: This was a phase I/IIa study involving a response-evaluable set of breast cancer patients.
• SIGNIFICANCE: Results suggest CDK2/4/6 inhibitors may enhance treatment outcomes when combined with endocrine therapy.